Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

Deep Value In This Diagnostic Company Might Attract Activists

Despite 2013 being one of the best years for IPO's in recent memory, shares of Liposcience (NASDAQ:LPDX), which went public at $9, quickly rose to $11 only to plummet to $4 by the end of the year.

The company faced challenges on many different fronts in 2013. After a profitable 2012, the company lost $12.5 million in 2013. While test volume increased 6% for the year, reimbursement per test declined at a greater pace of 10%, creating 200 basis points of gross margin compression. In addition, the company's operating expenses rose nearly $10 million in 2013, while sales fell more than $2 million. Despite these displeasing figures, there are reasons for optimism.

When I first wrote on Liposcience...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details